ONCOLYTICS BIOTECH INC (ONC.CA) Stock Price, Forecast & Analysis
Canada - TSX:ONC - CA6823108759 - Common Stock
ONC.CA Key Statistics, Chart & Performance
The current stock price of ONC.CA is 1.42 CAD. In the past month the price decreased by -7.19%. In the past year, price increased by 5.97%.
ONC.CA Latest News, Press Relases and Analysis
ONC.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 455.40M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 397.36M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 186.37M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 122.61M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.25 | 53.19M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.48M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.67M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 20.27M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 15.64M | ||
| MPH.CA | MEDICURE INC | N/A | 11.07M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.62M | ||
| TELO.CA | TELO GENOMICS CORP | N/A | 7.03M |
Related stock screener links
About ONC.CA
Company Profile
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Company Info
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 28
Phone: 14036707377
ONCOLYTICS BIOTECH INC / ONC.CA FAQ
What does ONCOLYTICS BIOTECH INC do?
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Can you provide the latest stock price for ONCOLYTICS BIOTECH INC?
The current stock price of ONC.CA is 1.42 CAD. The price increased by 2.16% in the last trading session.
Does ONCOLYTICS BIOTECH INC pay dividends?
ONC.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ONC stock?
ONC.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ONC stock?
ONC.CA stock is listed on the Toronto Stock Exchange exchange.
ONC.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ONC.CA. When comparing the yearly performance of all stocks, ONC.CA is one of the better performing stocks in the market, outperforming 91.32% of all stocks.
ONC.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONC.CA. While ONC.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ONC.CA Financial Highlights
Over the last trailing twelve months ONC.CA reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 2.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.26% | ||
| ROE | -499.46% | ||
| Debt/Equity | 0.1 |
ONC.CA Forecast & Estimates
8 analysts have analysed ONC.CA and the average price target is 4.6 CAD. This implies a price increase of 224.02% is expected in the next year compared to the current price of 1.42.